cerrar
Tagged with BIA

2019 A Boom Year for UK Biotech, Despite Brexit Concerns
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry's…

Saudi Arabia’s Bold Ambition to Become a Regional Pharma Hub
Saudi Arabia is aiming to become a more attractive investment destination for multinational pharma companies through economic development projects…

Central & Eastern Europe Pharma Market Snapshot
Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech…

Zhengyu Yuan – President & CEO, MicuRx
Dr. Zhengyu Yuan, president & CEO of MicuRx, shares the story of how MicuRx was founded in 2007 to develop new and innovative antimicrobial drugs;…

10 Global CEOs PharmaBoardroom Interviewed in 2018
Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global…

Manuel Ramos Ortega – Chairman, Labiana, Spain
Manuel Ramos Ortega, chairman of Labiana, a Spanish CDMO, highlights his strategy to create company stability and discusses the major trends in the…

Jungtae Park – Senior Managing Director, KoBIA, South Korea
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge…

Antonio Portela – CEO, Bial
Antonio Portela, seven years into leading the Bial operation in Portugal, shares his views on internationalization and how to maintain a stable…

Interview: Steve Bates – CEO, BioIndustry Association…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK's status as a global life science hub,…

Serbia Facts & Figures Snapshot
Serbia macroeconomic factsheet including data on population, GDP, education and life expectancy. Serbia has risen 50 places in the World…

Natural Products and Supplements in Serbia: A Growth Spot
In a market environment that, up until recently, has been severely difficult for producers of chemical pharmaceutical products to operate in, three…

Market Access in Serbia: Steps in the Right Direction
Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here